Oral Semaglutide 50 mg for Weight Loss in Chinese Adults

Overweight and obesity are growing global health challenges, significantly increasing the risk of numerous chronic diseases like type 2 diabetes, cardiovascular disease, and certain cancers. Effective and convenient weight management strategies are crucial to combat this epidemic. Despite the proven efficacy of injectable GLP-1 receptor agonists, there remains a need for accessible oral formulations, and this Phase 3 study, OASIS 3, was designed to specifically investigate the efficacy and safety of a high-dose oral semaglutide (50 mg) once daily in Chinese adults with overweight or obesity, addressing a specific demographic and a higher dose regimen.

While specific results for the OASIS 3 trial are currently pending publication, this Phase 3 study was designed to demonstrate significant body weight reduction. Based on the established efficacy of semaglutide as a GLP-1 receptor agonist (a type of drug that mimics a natural hormone to regulate appetite and food intake), it is anticipated that the semaglutide 50 mg group will show a substantial decrease in body weight compared to placebo. Previous studies with lower doses of oral semaglutide have shown average weight reductions of 5-10%, and injectable versions up to 15-20%. > It is expected that the oral semaglutide 50 mg group will achieve a statistically significant average body weight reduction, potentially in the range of 15-20% from baseline, compared to a modest 2-3% reduction in the placebo group. Furthermore, the trial is expected to report improvements in secondary endpoints such as BMI, waist circumference, and potentially cardiometabolic markers, with a higher proportion of semaglutide-treated participants achieving 5% and 10% weight loss targets. The safety profile is anticipated to be consistent with other GLP-1 receptor agonists, primarily involving mild to moderate gastrointestinal adverse events.